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Candida albicans is a polymorphic fungus that can grow as yeast (Y) and hypha (H). The
Y-H morphological switching is controlled through the MAPK, Cek1p. With the prior work
showing that occidiofungin prevents C. albicans from forming hypha when added at the time of
Y-H switching, we aim to identify the impact of occidiofungin on signaling events associated
with morphological switching specifically looking at Cek1 MAPK cascade. Results from this
work have demonstrated that Cek1 MAPK is not required for occidiofungin bioactivity. Further,
we report that morphologically switching cells are more sensitive to occidiofungin than their
non-switching counterparts. Moreover, later stages of hyphal formation exhibit increased
sensitivity towards occidiofungin suggesting occidiofungin targets hyphal initiation and/or
elongation process. This work also demonstrates that addition of occidiofungin beyond a discrete
time window required for hyphal initiation has minimal effect on hyphae formation and
elongation.
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CHAPTER I
INTRODUCTION
Invasive Candida Infections
Fungal infections are a major human health concern especially among the immunocompromised and hospitalized patients. The majority of life-threatening fungal diseases have
been associated with three major species of fungi: Candida albicans, Aspergillus fumigatus, and
Cryptococcus neoformans 1,2. Invasive candidiasis is an infection caused by Candida species.
The estimated number of annual candidiasis cases in the United States is approximately 46,000 3,
with candidemia being the most common form of invasive candidiasis. Candidemia is
characterized as a fungal blood stream infection (BSI). In the United States, 8% to 10% of the
total nosocomial BSIs acquired in a hospital setting are due to Candida species 4,5 with neonatal,
surgical, hematological, and burn unit patients at the highest risk 6. Of these, C. albicans, C.
glabrata, C. parapsilopsis, C. tropicalis, and C. krusei account for the majority of all invasive
Candida infections with C. albicans, the most common isolate, making up one-third of the
candidemia cases in the U.S.1,7,8.
Of recent concern is a study reported by the CDC indicating that Candida auris is an
emerging cause of invasive infections in healthcare settings 9. C. auris has been found to colonize
on patients and serve as a source of transmission in hospital settings. Most strains of C. auris are
found to be resistant to at least one antifungal drug, one-third are resistant to two antifungal drug
classes, and some strains exhibit resistance to all antifungal drugs used for treatment 10. C. auris
1

is often misidentified as other yeasts (e.g., Candida haemulonii) by conventional laboratory
techniques, making detection and control challenging 9. Because of these factors, the CDC has
alerted U.S. healthcare facilities to be on the lookout for patients that acquired C. auris
infections.

Table 1.1

a

Causative agents of opportunistic mycosesa

Organismsb
Yeasts
Candida species
C. albicans
C. glabrata
C. parapsilosis
C. tropicalis
C. krusei
C. lusitaniae
C. rugosa
C. guilliermondii
C. inconspicua
C. norvegensis

No. of cases/million/year

Case/fatality ratio

72.8

33.9

Cryptococcus species
Other yeasts
Hyaline molds
Aspergillus species
Zygomycetes
Other hyalohyphophycetes
Dematiaceous molds
Pneumocystis jiroveci

65.5

12.7

12.4
1.7
1.2
1.0

23.3
30.0
14.3
0

Data abstracted from the study of Reese et al. [source: 11]
This list not all-inclusive.

b

Epidemiology of Invasive Candidiasis
Candidemia can develop into a deep-seated infection which can result in fungal invasion
of internal organs 12 and has approximately 30% to 40% crude mortality rate 7. The difficulty in
2

early and accurate diagnosis of a fungal infection and the unidentified evidence for disseminated
fungal infection contribute to a high case fatality rate 13. The incidence of candidemia correlates
with patient age with older individuals being more susceptible. However, patients having
undergone an organ transplant, with acute or chronic leukemia, or patients in intensive care units
(ICUs) are particularly at high risk. Recent data indicates that the incidence of Invasive Fungal
Infection (IFI) is 2-11% in patients with different types of leukemia 14. Candida species have
been ranked the fourth most common cause of BSI in the U.S. accounting for more than 80% of
all fungemia cases 6. C. albicans and non-albicans Candida (NAC) spp. account for half of all
cases of candidemia and invasive candidiasis. Among non-albicans Candida species, patient
outcomes appear to be the least promising for C. glabrata 6.
Candidemia not only increases patient mortality but also the length and cost of hospital
stays. The estimated annual economic loss from each case of candidiasis is approximately
$40,000 U.S. 15. A number of host and health care-related factors contribute as predisposing
factors for candidemia (Table 1.2). For example, NAC occur more commonly in patients with
hematological malignancy, patients in intensive care units (ICU), and patients receiving systemic
therapy 16.

3

Table 1.2

Risk factors for invasive candidiasis

Risk factors for adults
Hematological malignancies
Long term Intensive Care Unit stay
Renal failure
High APACHE II (Acute Physiology and Chronic Health Evaluation) score
Organ transplantation
Severe acute pancreatitis
Hemodialysis
Neutropenia
Use of broad-spectrum antibiotics
Use of antifungals agents
Solid organ tumors
Glucocorticoid use or chemotherapy for cancer
Use of immunosuppressants
Colonization of Candida species
Surgical procedures
Use of central vascular catheters
Patient under ventilation
For neonates and children
Premature birth
Reduced birth weight
Congenital malformations
Source: New England Journal of Medicine (2015), 373(15), 1445–1456.
Candida albicans: Introduction
C. albicans is an important medically relevant opportunistic pathogen that can result in
superficial and disseminated fungal infections in humans. This fungus asymptomatically
colonizes the oral cavity, the urogenital tract and the gastrointestinal tract of healthy humans but
can also cause superficial to systemic fungal infections within immune-competent and immunecompromised hosts 1,17. Invasive candidiasis is a major concern to public health especially
among immunocompromised individuals like HIV patients, and individuals that have undergone
organ transplantation or received chemotherapy 1. Infections caused by C. albicans are
categorized as: asymptomatic colonization, superficial infection, deep-seated infection, and
4

disseminated infection. Colonization is as a result of the adherence of yeast cells to a mucosal
surface without any harm to its host. Most colonization events are asymptomatic. A superficial
infection occurs when the fungi penetrate the mucosa through fungal protease-mediated
degradation of host proteins. This may lead to a systemic infection under conditions when the
host’s innate immunity is altered or suppressed. Oral and vaginal candidiasis are examples of
common superficial Candida infections 18. Deep-seated infections are due to tissue penetration.
Generally, tissue invasion is facilitated by pathogen associated virulence factors such as hypha
formation and hydrolase secretion, but in some cases hyperactivation of immune response can
result in host-driven tissue destruction 19,20. Disseminated infections are common in hospitalized
patients and immune-compromised patients and include life threatening infections of the blood
stream and internal organs 17,21.
Morphogenesis: Yeast, Pseudohyphae, and True Hyphae
C. albicans is a polymorphic fungus that can undergo a complex series of morphogenetic
transformations between budding yeast, elongated pseudohyphae, and true hyphae 22. C. albicans
can also form chlamydospores and switch between white and opaque cells based on growth
conditions. Unlike other dimorphic pathogenic fungi (Histoplasma capsulatum, Paracoccidiodes
brasilensis, Penicillium marneffei) which grow in their filamentous form outside the host body
and convert into a pathogenic yeast form to invade host tissue, C. albicans is able to switch from
non-pathogenic yeast to pathogenic hyphae within the host 23. This ability of C. albicans to
change morphological phenotypes (yeast-to-hyphae) in response to environmental cues is
referred to as plasticity and is an important attribute for virulence 24.
The yeast form is characterized as cell growth by budding, whereas pseudohyphae and
true hyphae are both considered filamentous forms of the fungi 25. While hyphae and
5

pseudohyphae are considered invasive 26 and have a role in tissue penetration during infection,
the yeast morphology facilitates fungi dissemination in the bloodstream 27. Pseudohyphae are
considered an intermediate morphology between yeast and hyphae and are formed from yeast
cells that undergo polarized growth without fully separating following cell cycle completion.
Although pseudohyphae undergo polarized growth, they are morphologically distinct from true
hyphae. One distinguishing difference between these two morphological forms is cell shape 28.
Pseudohyphal cells possess a constriction at the junction between the mother and daughter cell.
In contrast, true-hyphae develop from an unbudded yeast cell and forms as a long parallel sided
tube-like filament with no constriction at the mother-daughter cell junction 28. In addition, the
length and width of pseudohyphae can vary, resembling that of hyphae or yeast cells with an
elongated bud, although typically pseudohyphal extensions are wider than that of true hyphae.
C. albicans can grow invasively in tissues and cause candidiasis by switching from the
non-invasive yeast form to the invasive filamentous form. As the acquisition of a filamentous
structure promotes host cell attachment and tissue invasion it is considered a major factor
controlling virulence 29 Tissue invasion is likely due in part to the release of fungal hydrolytic
enzymes 30. Three types of extracellular hyphal-associated hydrolases are secreted by C.
albicans: aspartyl proteinases (Sap), phospholipase B enzymes, and lipases. The decreased
virulence of hypha-deficient mutants has been linked to the modified expression of genes
encoding these hydrolytic enzymes 31,32. In addition, the hyphal morphology allows cells to
escape engulfment by macrophages which helps the fungi evade the host immune response 33.
For cells that have undergone phagocytosis, the hyphal expansion can induce phagosomal
membrane damage leading to alkalization of the lumen and macrophage death 34. The importance
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of morphological switching has been demonstrated in studies showing that C. albicans mutants
defective in filament formation are less virulent 32,35–37.
Cell Biology of Hyphal Growth
When a saturated culture of synchronized yeast cells is induced to form hyphae, a small
membrane extension, or germ tube, is formed. This hyphal projection is formed during the first
cell cycle and is different from pseudohyphae as the latter refers to an elongated bud 38. The term
‘germ tube’ and ‘true hyphae’ are often used interchangeably. Hypha, however, refers to
branched and unbranched filaments having one or more septa but no constriction at the mothercell neck 38. During germ tube formation, the filament extension is marked by a patch of septin
proteins that can be found as a ring at the base of the hyphae and a cap at the filament tip 22,39. In
contrast, in the case of yeast and pseudohyphae, the septum is formed between the mother and
the daughter cell. Septins at the germ tube tip remain fixed in this position as the tube elongates
22,40

. The first mitosis takes place with the nucleus migrating from the mother cell into the hypha

in a process controlled by the pulling activity of the microtubule motor protein, dynein 40.
Following mitosis, one nucleus is pulled back towards the mother cell and the other towards the
tip on the other side of the septin ring 22,41. The septin ring splits and an actomyosin ring forms
between them. Then a primary septum is formed between the two septin rings as a result of
actomyosin ring contraction. Further cell wall growth leads to secondary septum formation. The
primary septum is not hydrolyzed after formation of secondary septum, as in the case of yeast
cells, and the two daughter cell compartments remain attached to each other. This generates a
parallel sided long filamentous structure known as the hyphae 25,27.
With completion of the first cell cycle, the vacuole in the mother cell increases in size
resulting in a reduction in cytoplasm. Conversely, the hyphal compartment lacks vacuoles and
7

has a high proportion of cytoplasm. The small proportion of cytoplasm in the mother cell
maintains it in G1, but the hyphal cell will continue to elongate. With each cell cycle carried out
by the hyphal cell, the cytoplasmic volume of the mother cell decreases 42. Once the cytoplasmic
volume reaches a critical level, the vacuole decreases in size and the mother cell re-enters the
cell cycle to generate either a new hyphal branch from the site of septation or a different germ
tube from the mother cell 42. The branching process in hyphal cells, however, is slower than the
time it takes for it to move through the cell cycle, resulting in less frequent branching of hyphal
cells compared to pseudohyphae. Unlike hyphal cells, yeast and pseudohyphae cells undergo
nuclear division which takes place across the mother-daughter junction, and both cells re-enter
the cell cycle. This results in budded cells in yeast and highly branched structures with
constrictions in pseudohyphae 28,43.
Role of Actin in Polarized Growth
Polarized growth for both yeast and hyphae is dependent on polarization of the actin
cytoskeleton 44,45. The actin cytoskeleton of C. albicans consists of actin cortical patches and
actin cables. Cortical patches are a network of branched actin filaments which are found at sites
of polarized growth and function in endocytosis and cell wall remodeling 46 whereas actin cables
are bundles of cytoplasmic actin filaments aligned along the axis of the cell and have a role in the
transport of cargo to the daughter cell and are required for polarized growth 47. In hyphal cells,
the actin patches are concentrated at the hyphal tip of the growing cell irrespective of cell cycle
stage 27,48 and are uniformly distributed throughout the cell body. Actin cables, on the other hand,
are oriented towards the hyphae tip. In contrast, in case of yeast, the cortical patches are
dispersed throughout the daughter cell cortex and relocalize to the septum at the end of mitosis,
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while the actin cables are aligned within the axis of the budding cell. The actin cortical patches
function with actin cables to maintain polarized growth in both yeast and hyphae 27.
Actin cables are required for transport of secretory vesicles towards the daughter cell in
yeast and pseudohyphae and towards the hyphal tip in filamentous cells. Transport vesicles
derived from the trans-Golgi network (TGN) move along actin cables by Myo2 activity, the
actin-based motor protein complex. The Rho GTPase protein, Cdc42p, regulates polarized
growth and morphogenesis by regulating the formation of actin patches and cables at the site of
polarized growth, formation of septin rings, transport of secretory vesicles, and activation of
MAPK signaling cascade 49.
In C. albicans, the actin cytoskeleton plays a crucial role in the growth of all cell types.
Deletion of genes encoding actin cytoskeleton-regulatory proteins such as Sla1 50, Sla2 51, Pan1
52

, Wal1 53, Verproline (Vpr1) 54, or Myo5 55 lead to defects in hyphal growth and endocytosis.

The deletion of gene encoding the actin-related proteins, Arp2 or Arp3, has also been found to
lead to inhibition of hyphal formation 28.
Regulation of Hyphal Morphogenesis
Environmental Cues Inducing Hyphal Growth
The filamentous growth of C. albicans is regulated by multiple, overlapping intracellular
signaling pathways and are activated in response to various environmental cues 2,56 (Figure 1.1).
During the process of infection, C. albicans encounters various conditions within the host
capable of inducing filament formation including the presence of serum, elevated temperature
(37°C), elevated CO2 levels produced from cellular respiration, and nutrient deprivation 31. The
bacterial peptidoglycans released in human serum, and N-acetyl glucosamine (GlcNAc) released
from bacterial cell wall or the mucosal layer of the human GI tract are also major triggers of
9

filamentation 57–60. In a laboratory setting, synthetic media like Spider media or Lee’s media, in
combination with elevated temperature (37ºC), can be used. Both media are poor carbon and
nitrogen sources and are good inducers for filamentation, confirming that nutrient limitation can
stimulate morphogenesis 61.

`
Figure 1.1

Schematic representation of hypha induction in C. albicans

The environmental cues are sensed by the cell via different transmembrane sensor proteins and
signaling pathways are activated. Signaling pathways then activate transcriptional programming
that may converge on common target genes to trigger hyphal specific genes expression. Image
modified from figure 2 from: Microbiology (2000), 146, 1763-1774.

Major Signaling Cascade for Morphogenesis
Living cells sense changes in growth conditions through different signal transduction
pathways 62. The signaling pathway components and the associated transcription factors involved
in hypha induction have been well studied and reviewed in detail 23,63,64. These include two
positive regulators of hyphae specific gene expression: Efg1 and Cph1. Although these
10

transcription factors both regulate the expression of genes required for hyphal formation, they are
activated by different upstream signaling events 65. The Efg1 pathway is controlled through the
cyclic AMP (cAMP) signaling while the Cph1 pathway is based on Mitogen Activated Protein
kinase (MAPK) pathway signaling. The major signaling pathways and their components
involved in regulation of morphological transformation in response to environmental cues are
discussed below.
The Ras1 Protein Network Signaling
Ras is a small monomeric GTPase that is highly conserved from yeast to humans. As a
monomeric GTPase, GTP bound Ras is in its active form while GDP bound Ras is in its inactive
form 66. The exchange of GDP and hydrolysis of GTP is catalyzed by guanidine nucleotide
exchange factors (Ras-GEFs) and Ras-GTPase-activating factors (Ras-GAPs), respectively. Two
Ras proteins have been identified in C. albicans, Ras1p and Ras2p. These proteins have
opposing roles where Ras1p is required for filamentous growth and virulence while Ras2p
antagonizes regulation through the cAMP pathway 67. In C. albicans, Ras1p is activated by the
guanidine exchange factor, Csc25 (also known as Cdc25) in response to serum addition or
nitrogen starvation. Activated Ras1 stimulates the activity of adenylyl cyclase, Cyr1 to increase
cAMP levels through the adenylyl cyclase associated protein (CAP), Srv2p 68. Active Ras1 is
converted to its inactive GDP bound state by the Ras-GTPase activator protein, Ira2 69. C.
albicans Ras1 regulates two downstream pathways; the Mitogen Activated Protein Kinase
(MAPK) pathway and cyclic AMP dependent Protein Kinase A (cAMP/PKA) pathway 70.
Homozygous mutants deleted for RAS1 have reduced virulence and are unable to form hyphae
71,72

. Ras2p is expressed at a fraction of Ras1 levels and has an opposite effect on intracellular

cAMP levels 67,72. Deletion of RAS2 has little impact on hyphae formation, however in the ras1
11

Δ/Δ background, ras2 mutant shows distinct filamentous growth defects, 67 confirming a
negative regulatory role for this protein in C. albicans morphogenesis.
cAMP/PKA signaling cascade
The cAMP/PKA pathway is highly conserved among eukaryotes and components of this
pathway are necessary for filamentation (Figure 1.2). cAMP, produced from ATP by adenylyl
cyclase (Cyr1) 56, positively regulates hyphal morphogenesis. In C. albicans, the addition of
glucose and serum to media increases cAMP levels in a Ras1 dependent manner. Although
Ras1p and Cyr1p are not necessary for growth, they are required for hyphal development. The
Gpr1 receptor is required for methionine induced yeast-to-hyphae transition in C. albicans 73,74,
while the induction of filamentous growth under nitrogen starvation conditions is mediated by
the transmembrane ammonium permease receptor protein, Mep2. Mep2 signals through both
cAMP/PKA and the MAPK signaling pathways in Ras1 dependent manner 75.
cAMP activates protein kinase A (PKA); a heterotrimeric protein complex composed of
one regulatory subunit, Bcy1, and its catalytic subunits, Tpk1 and Tpk2. cAMP binding to Bcy1
76

induces a conformational change leading to release of the regulatory subunit from its catalytic

domain thereby activating kinase activity. The downstream regulator of the cAMP pathway is the
transcription factor Efg1. Tpk2 PKA mediated phosphorylation of Efg1 results in transcriptional
activation of large number of genes involved in hyphae formation including ECE1, HWP1,
HYR1, RBT1, and RBT4 77. These genes code for proteins essential for mucosal infection and
fungal cell attachment to host epithelial cells78. Deletion of EFG1 results in a media-dependent
defects in hyphal growth 79.
Termination of signaling through cAMP is mediated by two phosphodiesterases, Pde1p
and Pde2p, that negatively regulates the level of cAMP. Pde2p functions enzymatically to
12

convert cAMP to 5’AMP whereas Pde1p represses cAMP signaling in response to glucose 80.
Homozygous deletion mutants of PDE2 have elevated cAMP, a hyper filamentation phenotype,
and reduced virulence 68,81. Pde1p, however, is considered to have minor role in virulence but not
in morphogenesis 72.

Figure 1.2

Cyclic AMP dependent protein kinase A signaling pathway

A schematic showing the cAMP/PKA signaling pathway in C. albicans. The sensor proteins,
upstream signaling molecules, the signaling cascade, and the resulting biological responses are
shown. Image modified from figure 6.2 from: Advances in Applied Microbiology (2009), 67,
191-212.
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Mitogen Activated Protein Kinases (MAPK) signaling cascades
Mitogen activated protein kinase (MAPK) transduction pathways are widespread
signaling cascades that are present in eukaryotic cells 82. Typically, these signaling cascades
include a three-kinase system: a MAP kinase (MAPK), a MAP kinase kinase (MAPKK), and a
MAP kinase kinase kinase (MAPKKK). The MAPKKK phosphorylates MAPKK which in turn
phosphorylates MAPK 63. The MAPK then phosphorylates a target transcription factor to convert
the original signal into a transcriptional response. Three MAPK signaling cascades have been
identified in C. albicans for their role in filament formation and include the high osmolarity
glycerol (HOG) pathway, the cell wall integrity pathway (Mkc1 pathway), and the Cek1/Cek2
pathway (Figure 1.3). The HOG pathway is activated in response to osmotic and oxidative stress
63

; the Mkc1 pathway is activated in response to temperature and oxidative stress and has a role

in cell wall repair and biofilm formation 83; the Cek1 MAPK pathway is involved in hyphae
development, cell wall biogenesis and has role in virulence; and the Cek2 pathway is important
for mating 63,84,85.
The HOG Pathway
In C. albicans, four major proteins are identified as osmo-sensors for the HOG pathway:
Sln1, Nik1, Chk1, and Sho1. Sln1p has a major role in oxidative stress tolerance and
morphogenesis 31 while Sho1 has only minor role in HOG signaling pathway 31,86. SLN1 codes
for a plasma membrane protein that functions with Ypd1 as a two-component histidine kinase.
Under non-stress conditions, Sln1p is auto-phosphorylated which leads to a constitutively active
form of Sln1p and Ypd1p. Ypd1 phosphorylates Ssk1 which blocks downstream signaling 56,63.
Under stress conditions, autophosphorylation of Sln1p does not occur and Ypd1p is retained in
an inactive form. This results in the accumulation of the non-phosphorylated form of Ssk1,
14

which in turn promotes phosphorylation and activation of the downstream MAPKKK,
Ssk2/Ssk22p. Ssk2p phosphorylates Pbs2p, a MAPKK, which in turn phosphorylates, the
MAPK, Hog1p. Hog1p translocates from the cytosol to the nucleus where it acts as a
transcription factor, binding to target promoters to upregulate the expression of genes required
for stress response. Hog1 MAPK is reported to repress the yeast-to-hypha transition by
dephosphorylating and hence inactivating Cek1p 85. However, this Hog1 mediated yeast-tohyphae repression is not dependent on transcription factors Efg1 or Cph1. Not surprisingly,
mutants for hog1 or pbs2 exhibit enhanced true hyphae formation. Although Sln1p is the major
sensor for the Hog1 pathway, two other two-component histidine kinases, Nik1 and Chk1, can
function as upstream osmo-sensors for this signaling cascade. In C. albicans, the null mutants for
NIK1 or CHK1 have significant defects in hyphal formation on solid media but not in liquid
media. Although Sho1p is primarily involved in the Cek1 pathway, it can also trigger Hog1
activation suggesting a link between oxidative stress and morphogenesis in C. albicans (Figure
1.2) 31,56.
The Cek1/Cek2 mediated pathway
The Cek1 MAPK (Candida ERK-like kinase) pathway consists of the kinases Cst20,
Ste11 (a MAPK kinase kinase), Hst7 (a MAPK kinase), and Cek1 (a MAPK). The pathway was
first studied in 1992 by Whiteway et al., and was identified for its role in cell wall construction,
morphogenesis, and mating 87.
The Cek1 MAPK pathway is regulated through two plasma membrane proteins: Msb2
and Sho1p. Msb2p work in cooperation with Sho1p to influence Cek1p phosphorylation and
their inactivation results in defective hypha formation 88. Signal transduction between these two
receptor proteins and Cst20 is mediated by Cdc42p. Cst20 can also be directly activated by
15

Cdc42p in the absence of Msb2 binding. Cdc42p, together with its regulatory subunit, Cdc24p,
interacts with Ras1p to activate Cst20p by phosphorylation 89,90. Activated Cst20p in turn
phosphorylates the MAPKKK, Ste11, which then phosphorylates the MAPKK, Hst7p. Hst7p
then phosphorylates the MAPKs: Cek1 and Cek2. Activated Cek1/Cek2 phosphorylate the
transcription factor Cph1 which induces the expression of hypha specific genes. Although the
Cek1 MAPK pathway is important for hyphae formation, it is not essential. For example, the
cph1 transcription factor mutants have delayed filamentation but exhibit normal filaments in the
presence of serum 91 and a similar result was found for homozygous deletion of the kinases in
this pathway (CST20, STE11, or HST7) 92.
Cek1p activity is also regulated by two quorum sensing (QS) molecules, farnesol and
tyrosol 93,94. Farnesol is a natural organic compound (acyclic sesquiterpene alcohol) that inhibits
hyphal formation in stationary phase cells. Tyrosol is a phenylethanoid, a derivative of phenethyl
alcohol that is involved in accelerating growth of germ tubes by removing the lag phase for cells
diluted into fresh media. Studies have shown that farnesol reduces the expression of two
components of the Cek1 MAPK pathway, HST7 and CPH1 95. Moreover, farnesol prevents
activation/phosphorylation of Cek1p. Release from QS molecules and restart of growth by
diluting into fresh media transiently activates Cek1 MAPK and triggers hyphal formation 86,96,97.
The activity of Cek1p is negatively regulated by the phosphatase activity of Cpp1 and Hog185,98.
Given their negative regulatory activities, cells deleted for cpp1 or hog1 mutants have a hyper
filamentation phenotype 99.
Another MAPK, Cek2 (homologous to Fus3 in S. cerevisiae), has a role in mating 100.
Cek2 activates Cph1 transcription factor to induce the expression of mating genes. However, the
exact signaling pathway and their functions are poorly described in C. albicans.
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Figure 1.3

Mitogen Activated Protein Kinase signaling pathways

A schematic showing the relationship between three MAPK signaling pathways in C. albicans.
The upstream signaling molecules, their membrane localized receptors, the intracellular signaling
cascades, and the resulting biological responses are presented. Image is modified from figure 1
from: Virulence (2012), 3(3), 251-261.

The Cell Wall Integrity Pathway (Mkc1 Pathway)
The cell wall integrity pathway is one of the best characterized MAPK pathways in C.
albicans. The basic kinase system of this pathway consists of Pkc1 (Protein Kinase C), Bkc1
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(bypass of protein kinase C) a MAPKKK protein, Mkk1/Mkk2 a MAPKK, and Mkc1 a MAPK.
This pathway is activated in response to stress conditions including elevated calcium levels,
changes in osmolarity, oxidative stress, temperature shock, and exposure to antifungal agents 83
and partially overlaps with that of the Hog1p pathway. Recent work has indicated that Mkc1p
has an essential role in biofilm formation and invasive growth 101. Overexpression of Mkc1 was
shown to enhance pseudohyphae formation while Mkc1 mutants have been reported to have
decreased virulence 83,102.
pH Regulated Pathway
C. albicans can colonize in a broad range of host niches, including the bloodstream where
the pH is 7.0 and the vagina where pH is 4.5. The ability to survive in different pH environments
is an important factor for Candida pathogenicity and has been linked to morphogenesis with
hyphal development occurring best at neutral pH while yeast growth favors an acidic pH. The
central regulator of the pH-mediated signaling pathway is Rim101, a zinc finger transcription
factor. The activity of Rim101 is controlled by proteolytic cleavage. Under alkaline condition,
Rim101 is proteolytically cleaved by Rim13p, releasing the inhibitory carboxy-terminus to
generate an amino-terminal transcriptional regulator. The transmembrane spanning proteins,
Rim21p, Rim8p, and Dfg16p are upstream of the proteolytic step that act as environmental pH
sensors 103,104. Once cleaved, Rim101p binds to the consensus sequence within the promotor
region of alkaline induced genes and amplifies the signal for upregulation of pH regulated genes
105

. Deletion of RIM101, or the genes that activate Rim101 in C. albicans, shows defects in

filamentous growth in media like Lee’s media and alter the expression of two pH regulated
genes, PHR1 and PHR2 106. PHR1 is expressed at alkaline pH (pH ≥5.5) while PHR2 is
expressed under more acidic conditions (pH <5.5). Each codes for glycosidases involved in
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cross-linking cell wall glucans 107,108. PHR1 is upregulated in hyphal cells and has a role in
maintenance of hyphal growth. Homozygous deletion mutants of PHR1 have filamentation
defects at neutral to alkaline pH and show reduced virulence in mouse model of systemic
infection (neutral pH) but are capable of establishing a vaginal infection (acidic pH). Deletion of
PHR2 reduce filamentous growth under acidic pH conditions, and exhibit normal systemic
infection but are avirulent in vaginal infection 109.
Negative Regulators of Filamentous Growth
The pathways mentioned above are all involved in positively regulating hyphae
formation. However, there are several negative regulators of morphogenesis in C. albicans.
Tup1p was the first identified transcriptional repressor that maintains cells in their yeast form as
cells deleted for TUP1 form pseudohyphae or true hyphae in all media conditions 79. The genes
required for initiation of filamentous growth such as HWP1, RBT1, RBT2, RBT4, RBT5, RBT7
and WAP1 are all repressed by Tup1 activity. Epistasis based studies indicated that Tup1 activity
is independent of the transcriptional activators, Efg1 or Cph1 65. Studies suggest that Tup1 may
have a role in quorum sensing, as farnesol treatment lead to an upregulation of Tup1p levels.
Two additional transcriptional repressors that work with Tup1 include Nrg1 and Rfg1 56.
Together, nearly half of the hyphae-associated genes induced in response to serum and high
temperature are repressed by the combination of these three proteins. Nrg1 is a zinc-finger DNA
binding protein that recruits Tup1 to the promotor of target genes including ECE1 and HWP1
110,111

. Similar to that seen for tup1, deletion of NRG1 results in cells that are predominantly in

hyphal form under non-hyphae inducing conditions 31. Rfg1 is a high mobility group domain
(HMG) containing DNA binding protein that also recruits Tup1 to hypha-specific promotors to
induce repression 112. Deletion of RFG1 has also been reported to lead to filamentous growth 113.
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Commonly Used Antifungal Agents
Invasive fungal infections are emerging as a major global problem among the immunecompromised individuals and a challenge to treat, resulting in at least 1.5 million deaths
worldwide each year 114,115. It is estimated that the annual treatment cost for invasive fungal
infections is ~ $2.6 billion in the United States, with significant proportion of these expenditure
going towards antifungals 116. Invasive candidiasis is most common, accounting for 30%-40% of
the fungal mortality cases, followed by 20%-30% mortality by Cryptococcosis and Aspergillosis.
In addition to these common fungi, emerging fungi such as Pneumocystis, Mucor, Rhizopus,
Zygomycetes, Scedosporium, and Fusarium can cause invasive infections 117,118. The treatment of
IC is a challenge due to increasing incidence rates (particularly C. glabrata) and decreasing
susceptibility to common antifungals 119. Even fungi that cause superficial, cutaneous, or
subcutaneous infections are a concern as they can diminish the quality of life of infected
individuals and impact more individuals than invasive infections.
The antifungals used in clinical settings for treatment of fungal infections are grouped
into four classes based on their mechanism of action. Group I compounds are nucleic acid
synthesis inhibitors and include 5-fluorocytosine (5-FC). Group II include polyenes (nystatin,
natamycin, and amphotericin B) which disrupt plasma membrane integrity. Group III compounds
inhibit cell wall biosynthesis and include echinocandins (caspofungin, micafungin, and
anidulafungin). Group IV includes allylamines (terbinafine and naftifine) and azoles
(fluconazole, miconazole, itraconazole, and voriconazole) which function as inhibitors of
ergosterol biosynthesis 120–122. Each of these antifungals has drawbacks associated with them that
includes limited spectrum of activity and high toxicity to human host 115,123. However, a larger
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concern is the identification of strains resistant to the current antifungal agents which is creating
a need for new drugs having unique biological targets and different modes of action 123.
Nucleic Acid Inhibitors: 5-FC, 5-fluorocytosine
Flucytosine (5-fluorocytosine) is a commonly used antifungal for the treatment of
candidiasis. It is a fluorinated pyrimidine analog that interferes with pyrimidine metabolism
resulting in inhibition of nucleic acid and protein synthesis 124. The compound is transported into
fungal cells through the activity of a cytosine permease. Once internalized, flucytosine is
converted to 5-fluorouracil (5-FU) by cytosine deaminase followed by conversion to 5flurouridine monophosphate (5-fluoro-UMP) by the enzyme uracil phosphoribosyl transferase
125

. 5-fluoro-UMP is further phosphorylated to fluoro-UTP which can be incorporated into RNA

in place of UTP. This incorporation alters the aminoacylation of tRNA and results in protein
synthesis inhibition. Conversion of 5-fluoro-UMP to 5-fluorodeoxyuridine monophosphate
inhibits DNA synthesis and nuclear division as the compound targets the enzyme, thymidylate
synthase. In both cases, the end result is fungal cell death 126,127. Flucytosine is effective against
many yeasts including Candida and Cryptococcus. Studies have shown that Candida spp. that
have developed resistance to flucytosine have acquired mutations in enzymes involved in the
cellular uptake and metabolism of flucytosine, or the modification of flucytosine to 5-fluoroUMP 128.
Membrane Function Disruptors: Polyenes
Polyenes are derived from Streptomyces spp. and were the first drugs used clinically to
treat fungal infections 120,129. Polyenes are characterized as macrolides having a 20-40 carbon
macro-lactone ring. They primarily target plasma membrane localized ergosterol to generate
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pores. These pores disrupt plasma membrane integrity leading to cell death through the leakage
of cytoplasmic content and oxidative damage 121,127. Nystatin, natamycin, and amphotericin B
(AMB) are commonly used polyenes. Nystatin is widely used for treatment of superficial
infections; natamycin is drug of choice for treating fungal keratitis caused by filamentous fungi
130

. AMB is considered the gold standard for the treatment of various of fungal infections

including Candida spp., Aspergillus spp., Cryptococcus spp., Mucor spp., Rhizopus spp.,131
Trichosporon spp., Scedosporium spp., and Malassezia spp. 131,132. Despite their years of use,
resistance to polyenes is considered rare in C. albicans. However, several non albicans Candida
species are reported to be resistant to AMB due to decreased plasma membrane ergosterol levels
in these fungi 127,133.
Membrane Function Disruptors: Echinocandins
Echinocandins are the newest class of antifungal agents approved by the FDA for clinical
use 131. Echinocandins are semisynthetic lipopolypeptide molecules derived from natural
products by Aspergillus rugulovalvus, Zalerion arboricola, and Papularia sphaerosperma 131.
Echinochandins function as noncompetitive inhibitors of β-1,3-D-glucan synthetase, an integral
membrane protein encoded by FKS1/2. This complex consists of two subunits: the active site
subunit, Fks1p, and the regulatory subunit, Rho1p. The enzyme is required for synthesis of 1,3glucan, a crucial component of the fungal cell wall 127. Loss of glucan synthase activity leads to
disruption of cell wall biosynthesis and fungal cell death 120,134. Currently, three echinocandin
members are used for treatment of fungal infections: caspofungin, micafungin, and
anidulafungin. These echinocandins are fungicidal against many strains of Candida however
they are fungistatic against Aspergillus spp. 120 and are ineffective against Cryptococcus,
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Trichosporon, Scedosporium, and Fusarium species 119. Resistance to echinocandin has been
linked to mutations in the FKS1 gene 121 that alter the echinocandin binding site 135.
Inhibitors of Ergosterol Synthesis: Allylamines
Allylamines inhibit the activity of squalene epoxidase (Erg1p), an early enzyme in
ergosterol biosynthesis that converts squalene to 2,3-squalene epoxide. Fungal cell death is
primarily due to the accumulation of squalene inside the cell rather than deficiency of ergosterol
as elevated levels of squalene result in increased membrane permeability and disruption in cell
organization 117,136. Allylamines are fungicidal against dermatophytes and fungistatic against C.
albicans 121. Terbinafine and naftifine are example antifungals from this group 121,137. Terbinafine
is widely used for treatment of skin, nails and hair infections and oropharangeal candidiasis and
can also be used for fluconazole resistant and itraconazole resistant fungi 138. Terbinafine is more
effective against C. albicans and C. parapsilosis than C. glabrata 137. Resistance to terbinafine
by C. albicans is linked to mutations that increase expression of the plasma membrane efflux
pumps CDR1, AGP2, and HOL3 which leads to reduced intracellular levels of the drug 139.
Inhibitors of Ergosterol Synthesis: Azoles
Azoles are the most commonly used antifungal agents and are the first choice for
antifungal therapy. Fluconazole, voriconazole, miconazole, itraconazole, econazole, and
posaconazole are widely used azoles for the treatment of human fungal infections 2,120. They are
fungistatic against yeasts including C. albicans and fungicidal against molds like Aspergillus
spp. 140. Azoles inhibit biosynthesis of ergosterol, a bioregulator of membrane fluidity and
membrane integrity, by targeting the enzyme required for ergosterol synthesis, lanosterol
demethylase (cytochrome P450) encoded by ERG11. This enzyme converts lanosterol to
23

ergosterol 2,121. Azoles bind to the heme group of Erg11p which prevents the oxygen activation
step required for the 14α-demethylation of lanosterol. This leads to the accumulation of a
methylated intermediate (14α-methyl fecosterol) which is converted to a methylated sterol (14-amethyl-3,6-diol) by Δ5,6 sterol desaturase enzyme (ERG3) resulting in the alteration of plasma
membrane structure and function 135. The fungistatic activity of azoles is therefore a result of the
inhibition of 14α-methylase enzyme and the accumulation of the toxic sterol byproduct 118,141.
Trend of Antifungal Resistance
The proportion of Candida species resistant to first- and second-line antifungal drugs
such as fluconazole and echinocandins are increasing. Generally, resistance is acquired through
the accumulation of mutations or genomic alterations or through inherent resistance mechanisms.
Inherent resistance is an innate resistance to antifungals and in C. albicans this has been linked to
their ability to form biofilms that acts as a barrier to the bioactivity of antifungal compounds.
Additional factors like alteration in efflux pump expression, changes in cell wall and cell
membrane composition, alteration of drug target, and changes in cellular stress responses have
also been identified as potential antifungal drug resistant mechanisms 2,142. The emergence of
resistant Candida species has contributed to an increased mortality rate associated with fungal
infections globally. The prevalence of resistant non- albicans Candida species and the most
recent global threat posed by C. auris, has been more apparent recently 143. The CDC’s
surveillance over the past 2 decades (1992-1993, 1993-2000, 2000-2011) in two different areas
of the United States has indicated that the proportion of Candida isolates resistant to
echinocandins are increasing (1% of the isolates) while the rate of fluconazole resistance remains
unchanged (constant at 7%). However, C. glabrata is an exception, having higher resistant rates
for both fluconazole and echinocandins 7,8 likely as a result of an increased proportion of C.
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glabrata based blood stream infection (BSI) is increasing which has contributed the most to the
increased resistance detected for clinical isolates against fluconazole and echinocandins 144,145. It
was reported that fluconazole resistance during the study period increased significantly from 9 to
14% for C. glabrata. Another 10-year survey (2001-2010) in U.S. hospitals reported that
echinocandin resistance for C. glabrata increased from 4.9%-12.3% 146. These data suggest that
the increasing proportion of infections caused by C. glabrata could lead to further development
of resistance or even multi-drug resistance. More recently, C. auris has emerged as a cause of
invasive infections in hospital settings. About 30% of the isolates were found to be amphotericin
B resistant with some showing resistance to echinocandin. Although antifungal drug
combinations effectively target these strains, the identification of echinocandin resistance for a
newly identified fungal pathogen is a concern 9.
Antifungal Pipeline
The increase in severe systemic infections and the development of resistant fungal strains
has created an obvious need for new antifungal agents with unique mechanism of action. Despite
this need, there has been limited growth in the antifungal drug development pipeline. Traditional
antifungals interfere with essential biological processes to either kill or inhibit the growth of the
fungi. A more recent approach of targeting the morphological plasticity has been discussed as a
new paradigm for development of novel antifungals 147. To be effective, a new antifungal drug
should ideally have a broad spectrum activity, work against resistant strains, exhibit better
fungicidal activity, show reduced or no host toxicity, have improved pharmacokinetics and
pharmacodynamics, have minimal interaction with other drugs, and a unique biological target
and mechanism of action 120. No new drug has been approved by the FDA or the EMA
(European Medicine Agency) since anidulafungin (a member of echinocandin family) in 2006.
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However, several antifungal drugs are at different stages of development and are under
preclinical and clinical investigations. Most of the compounds in the antifungal pipeline are
derivatives of azoles, echinochandins, and polyenes and therefore have similar targets and
mechanism of action 120. Given the rise in antifungal resistant fungal pathogens, there is an
urgency for drug development against novel targets. Several antifungal drugs that show unique
modes of action have been identified and are in the process of preclinical development or are in
clinical trials 115,117,123. Most recently a new antifungal, occidiofungin, has been recognized as
having properties that make it a potential drug candidate.
Occidiofungin: A Novel Drug
Occidiofungin was identified as a secreted product of the soil bacteria Burkholderia
contaminans strain MS14 148,149. Structural analysis revealed that there are four variants
designated as occidiofungin A through D that vary in molecular weight due to the addition of
oxygen and/or chlorine to the first compound, occidiofungin A. All four variants are 8 amino
acid cyclic structures modified with the addition of a fatty amino acid and a sugar 148. The
nonribosomal synthesis of occidiofungin have been mapped to an ‘occidiofungin gene cluster
(ocf)’, a 58.1kb genomic DNA region containing 16 genes 148. Occidiofungin has broad spectrum
antifungal activity and is effective against both plant and animal fungal pathogens including
filamentous and non-filamentous fungi 150,151. Toxicological analysis in mice revealed that it was
well tolerated at doses up to 20mg/kg body mass with only a slight reduction in body and organ
weights. Histological studies indicated that the antifungal did not result in any organ specific
toxicity 151. Although not understood, the compound was also shown to be effective when tested
against human cancer cell lines 152.
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In support of its candidacy as a novel drug for clinical use, Ellis et al., determined the
chemical stability and in vitro potency of occidiofungin against Candida species. They reported
that occidiofungin activity is retained even after exposure to elevated temperatures (100°C),
extreme pH conditions (pH 2-9), and gastric proteases (trypsin, chymotrypsin and pepsin)
suggesting that occidiofungin could be used for oral administration 153. Furthermore,
occidiofungin was found active against fluconazole and echinocandin (caspofungin) resistant
strains of Candida 150,153. The fungicidal activity of occidiofungin could be detected within 30
minutes of exposure suggesting a strong interaction with its cellular target. Sublethal doses of
occidiofungin were shown to induce oxidative stress, trigger the cell wall damage response
pathway, and induce morphological defects including cell shrinkage and DNA fragmentation,
which together suggest an apoptotic mechanism of cell death 154. Another study by Robinson et
al., reported that the fungicidal activity of occidiofungin is enhanced 4-fold in the presence of
extracellular calcium with resistance independent of the calcineurin-calmodulin pathway 155. The
molecular mechanism behind this resistance is currently unknown.
Occidiofungin shows no interaction with ergosterol or β-1,3-glucan, the biological targets
for the common classes of antifungal compounds 154. A recent study by Ravichandran et al.,
reported actin as the molecular target of occidiofungin. These conclusions were based on the
findings that occidiofungin localized to actin rich areas in vivo. A direct interaction of
occidiofungin with actin was confirmed by in vitro streptavidin binding assays using purified Fand G-actin and biotinylated alkyne-occidiofungin. These results were further confirmed using
an actin co-sedimentation assay which is commonly used for identifying actin-associated
proteins. These in vitro findings were supported by in vivo studies demonstrating that exposure
of C. albicans cells to sub-inhibitory concentration of occidiofungin inhibited hyphae formation
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in cells that were induced for morphological switching, caused disruption to actin cables, and
induced nuclear DNA positioning defects. Furthermore, the efficacy of occidiofungin to treat
vulvovaginal candidiasis was demonstrated using a mouse model which suggested that
occidiofungin is more efficient in treating vulvovaginal candidiasis with less toxicity than other
actin binding antifungals previously reported 150. These combined findings support occidiofungin
as a strong candidate for potent novel antifungal for clinical use.
Objectives and Experimental Hypothesis
In this study, the main goal was to determine the impact of occidiofungin on
morphological switching of C. albicans from the yeast-to-hyphal form, specifically looking at
the impact on the MAPK signaling pathway. To achieve this, western blot analysis was carried
out to measure changes in the level of Cek1 MAPK activation in response to occidiofungin
exposure. In addition to using two different wild type C. albicans strains, Cek1 MAPK pathway
deletion mutants were also analyzed for altered susceptibility to occidiofungin using quantitative
(CFU analysis) and qualitative (spotting assays) measures. The relationship between occidiofungin
exposure and hyphal developmental timing was also characterized by light microscopy with the
hyphae versus yeast morphology scored and changes to hyphal length determined.
Considering the potential role of the dimorphism of C. albicans in pathogenesis of this
organism, an understanding of the susceptibilities of these two forms (yeast and hyphae) may help to
determine the relationship between the activity of occidiofungin and its effect on the morphogenetic
transformation of C. albicans. To this end, we identified the minimum concentration of
occidiofungin required to block morphological transformation and compared this data to MIC values
obtained to inhibit growth of yeast and switched cells.
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Given the previous findings that occidiofungin inhibits filamentation, and the established role
of Cek1 MAPK signaling pathway in filament formation, we hypothesized that occidiofungin blocks
hyphal formation in C. albicans through inhibition of Cek1 MAPK signaling pathway.
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CHAPTER II
MATERIALS AND METHODS
Strains, Media, and Reagents
C. albicans strains used in these experiments include: ATCC 66027, SC5314, and
DAY286. Homozygous deletion strains for Cek1 pathway mutants were obtained from the Aaron
Mitchell knock out library sets (Fungal Genetics Stock Center Candida resources) and included:
Δcph1/Δcph1, Δhst7/Δhst7, Δste11/Δste11 and Δcst20/Δcst20. All strains were stored at -80°C as
glycerol stocks and sub-cultured on fresh YPD agar plate before use. To induce morphological
switching, strains were grown in YPD broth media (2% peptone, 1% yeast extract, 2% glucose)
in a shaking incubator at 30°C for 48 hours to obtain a saturated culture with an OD600/ml of 1820. Spider medium (1% nutrient broth, 1% mannitol, 0.2% K2PO4) was used as the media of
choice to induce morphogenic switching at 37°C. For volume less than 2ml, cultures were
maintained in a 5mL polypropylene Eppendorf tube. For volumes of 20-30mls, switching was
carried out using polypropylene Erlenmeyer flasks (VITLAB). In all cases, cells were placed at
37°C without shaking to induce morphological switching. All media were prepared as described
156

.
Antifungal Preparation
The occidiofungin used in this study was a gift from Dr. James Leif Smith, Department

of Biology, Texas A&M University and was isolated from Burkholderia contaminans strain
MS14 as described by Gu et al., 2009 157. All stock and working concentrations of antifungal
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compounds were prepared in 100% DMSO and stored at -20°C until use. The working
concentrations of occidiofungin (1mg/mL and 0.4mg/mL) was prepared in DMSO from a
10mg/mL stock solution. Caspofungin was purchased from Sigma (SML0425) and used for
comparison of MIC values. A working concentration of 0.05mg/mL caspofungin was prepared in
100% DMSO.
Protein Extraction and Western Blot Analysis
C. albicans ATCC 66027 was grown in YPD at 30°C with shaking for 48 hours to obtain
a saturated culture. Cells from the saturated culture were diluted into Spider media to obtain an
OD600/ml of 0.05 (~1.66 x 106 cells/mL). The culture was split and occidiofungin was added to
one part to achieve 1µg/ml final concentration (1X MIC value) and an equivalent volume of
DMSO (vehicle) was added to the other culture. Cultures were placed without shaking at 37°C to
induce switching. At defined time points (T= 0, 0.5, 1, 1.5, and 2 hours), cells were collected
from both treated and untreated cultures by vacuum filtration through 0.2µm nitrocellulose disk.
Total protein was isolated by alkaline cell lysis method followed by TCA precipitation and the
resulting protein solubilized in SDS loading buffer (minus bromophenol blue dye) with bath
sonication 158. Total protein concentration was determined by A280 method and an equal amount
of protein was loaded onto a 12% SDS polyacrylamide gel (SDS-PAGE) and protein separated
by electrophoresis. Proteins were transferred to a nitrocellulose membrane followed by amido
black staining to confirm transfer and equal loading of samples. Detection of phosphorylated
Cek1 protein was done by western blot using commercially available anti-phospho-p44
antibodies (Cell Signaling Technology Cat# 4370, RRID: AB_2315112). Antibodies to
glyceraldehyde 3-phosphate dehydrogenase (Thermo Fisher Scientific Cat# PA1-987, RRID:
AB_2107311) was used as loading control. The primary antibodies were used in 1:6000 dilution
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using 5% BSA as a blocking agent with an overnight incubation at 4°C. Membranes were
developed using HRP-conjugated anti rabbit secondary antibodies (1:8000 dilution) in 5% nonfat dry milk along with Pierce Femto detection reagents. The resulting autoradiographs were
scanned and analyzed using NIH Image J software, with the intensity of phosphorylated Cek1p
compared to that of GAPDH to calculate relative fold differences compared to wild type. The
amount of phospho-Cek1p at 30 minutes of switching was normalized to 1.
Minimum Inhibitory Concentration (MIC) Assay
Minimum inhibitory concentration assays (MICs) were performed using a modified
microtiter-based assay that is based on Clinical Laboratory Standard Institute (CLSI) guidelines
155

. To obtain a synchronized yeast phase culture for switching studies, cells were inoculated into

fresh YPD broth media and incubated at 30°C for 48 hours with agitation. For studies using the
yeast form, cells were grown in YPD broth overnight at 30°C. Different conditions were used in
MIC assays on yeast versus hyphal fungi. For yeast phase, the antifungal susceptibility testing
was performed using an inoculum of 1 x 104 cells/mL and 1.66 x 106 cells/mL (equivalent to an
OD600/mL of 0.05). The overnight culture grown at 30°C was serially diluted in YPD to obtain
the desired cell concentration. For the treatment of cells induced to undergo hyphal formation,
cells from a saturated culture grown at 37°C were serially diluted in Spider media to obtain the
same final cell concentration as for yeast phase testing. The growth indicator, resazurin, was
added to diluted cells to obtain a final concentration of 0.005% for visualization of switching cell
growth in microtiter plate wells 159. In all cases, diluted C. albicans cells were added to a 96 well
tissue-culture treated microtiter plate with 200µL added to the first well and a 100µL volume
added to the remaining wells of the row. An appropriate amount of occidiofungin was added to
the first well to obtain a final concentration of 2µg/mL and a 2-fold serial dilution of the
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antifungal was achieved by transferring 100µL across the wells. MIC values were determined
after 24- and 48-hours incubation at 30°C for yeast form and 37°C for the hyphal form. For yeast
phase cells, the wells containing the lowest concentration of drug that showed no visible growth
were recorded as the MIC reading and for hyphal phase cells, the wells with lowest concentration
of drug that showed no color change (i.e. stayed blue color) were recorded as the MIC values.
Similar experiment was performed to determine the MICs for occidiofungin and
caspofungin on post-switching cells. In this case, cells at the inoculum density of 1.66 x 106
cells/mL were first placed in conditions to induce switching (Spider media, 37°C) for a period of
time (T= 0 or 1.5 hours) and then used in an MIC assay. Whenever tested, the MIC values for
mutant strains were compared with that of wild type strains carried out at the same time under
the same experimental conditions. At a minimum, all MIC assays were performed in biological
triplicate with technical duplicates included on all plates for all strains.
Microscopy
Microscopic analysis of cell morphology was carried out on C. albicans cells treated with
occidiofungin at the time of switching and on cells exposed to the drug at defined times after
switching induction. In all cases, cells were fixed with the addition of formaldehye to 3.7% final.
For DAPI staining, cells were permeabilized in 1X PBS, 0.1% TritonX-100 for 15-20 minutes at
room temperature. Cells were collected by centrifugation and resuspended in Vecta-Shield
containing DAPI. Cells were viewed using a Nikon Eclipse-50 microscope under 100X (1.25
N.A.) oil immersion objective. Images were captured using a black and white Retiga Camera and
QImaging software. Approximately 200 cells were scored for each sample with cells in all fields
categorized as either yeast or hyphae. Hyphal lengths for occidiofungin treated and untreated

33

cells were measured using NIH Image J software. The length measured from the base of mother
cell to the tip of the filament was taken as the hyphal length measurement 160.
CFU Determination and Spotting Assay
Assays were carried out as described 155. Essentially, cells were grown for 48-hours in
YPD at 30°C to reach saturation. Cells were diluted into Spider media to obtain a cell
concentration of 1.66 x 106cells/mL (OD600=0.05). At indicated time points (T=0, 0.5, 1, 1.5 and
2 hrs), 200µL of cells were transferred to the first column of a 96 well microtiter plate. Each
sample was then 10-fold serially diluted by transferring 25µL from one well to another well
containing 225µL of Spider media. For spotting assay, 3µl from each well was spotted onto YPD
media in duplicate and incubated at 30°C. Multiple photographic images were taken after 24 and
48-hrs incubation. For CFU determination, 50µL from selected dilutions were spread on YPD
plates and incubated at 30°C. Colonies were counted after 48-hrs of incubation. Plates having
colonies between 30-300 were only included in data for determining CFUs using following
equation:
CFU= N x 20 (dilution factor) x 10D-1
Where, N = # colonies on a plate
D = column # of corresponding dilution
The mean CFU at each time point was calculated and the values were plotted as Log10
values (average CFUs) versus time (hours). Percent cell death at each time point was calculated
as the relative difference between the average CFU/mL for occidiofungin-treated samples and its
corresponding control and compared with untreated samples 155.
.
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CHAPTER III
RESULTS
Occidiofungin Blocks Yeast-to-Hyphae Morphological Switching
It is well established that the expression of adhesin proteins by C. albicans results in cell
attachment to polystyrene-based plastics 161,162. In our hands, we also found that culturing in
glass flasks negatively impacted the number of cells that underwent morphological switching.
Therefore, to avoid the adherence of cells to the culture flask and to achieve the maximum
percentage of switched cells, only polypropylene tubes/flasks were used. Cell volume was also
critical. For induction of morphological switching of a 2mL or smaller culture, 5mL
polypropylene Eppendorf tubes were used; for larger volumes (20-30mL), polypropylene
Erlenmeyer flasks were used.
Although previous studies have shown that Candida strains are susceptible to the
antifungal, occidiofungin 150,153, its impact on the morphogenic transition required additional
investigation. To determine the effect the antifungal compound had on hyphae induction,
occidiofungin was added to cells that were diluted from a saturated culture into Spider media at
37°C and the resulting cellular morphology scored by microscopy over a 2hr time period. The
fungal morphology at T=0 hour were all that of unbudded cells, as expected for a saturated
culture 163. Similar to that reported recently, cells exposed to occidiofungin at the time of
switching did not form filaments at any point during the 2hr induction period and the cells
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remained unbudded. This was in contrast to untreated cells in which hyphal extensions could be
seen within 1 hour of switching induction (Figure 3.1) 150.

Figure 3.1

Montage of representative cell morphologies following occidiofungin exposure.

A 48-hr culture was diluted into Spider media to achieve an OD600 of 0.05 (equivalent to 1.66 x
106 cells/mL). Occidiofungin (1X MIC; 1µg/mL) or an equivalent volume of DMSO as the
vehicle control were added and cultures incubated at 37°C to induce hyphae formation. At
defined times (T=0hr, 0.5hr, 1hr, 1.5hr and 2 hr), cells were fixed with the addition of
formaldehyde and the resulting morphology scored as either yeast or hyphae by 100X light
microscopy. Size bar = 5 µm.

For untreated cells, morphological switching was detectable within 1 hour of incubation
at 37°C in Spider medium, with >80% of the cells in culture forming hyphal extensions by 2
hours incubation whereas 100% of the untreated cells were in the yeast form for all time points.
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Figure 3.2

Percent cell morphology of C. albicans under switching conditions.

Graphical depiction of cell morphology in occidiofungin treated and untreated C. albicans cells
at 0, 0.5, 1 and 2 hours post switching. Data are the average and standard deviation from at least
200 cells per sample for each treatment condition. The percent of yeast and hyphal cells from 3
independent experiments are shown.

Morphologically Switching Cells Are More Susceptible to Occidiofungin
There has been a number of studies on the antifungal susceptibility testing of C. albicans
for occidiofungin and those studies focused on susceptibility of yeast phase cells 150,153. Although
several studies have focused on effect of antifungals such as azoles, amphotericin B and
echinocandins on morphogenic transformation of C. albicans 164,165, no studies have been
performed to investigate effects of occidiofungin on the other morphological forms of C.
albicans including the filamentous form. Given the role that the filamentous form of the fungi
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plays in invasive infections, it is important to understand the action of antifungal agents on these
two morphological forms. Hence, we compared the MIC of occidiofungin for yeast-phase cells
with that of morphologically switching cells. Since morphologically switching cells produced
undiscernible growth in these assays, resazurin was used as an indicator for the identification of
wells with growth for MIC value determination. Data show that morphologically switching cells
of C. albicans were 2-fold more sensitive to occidiofungin than vegetative growing cells
indicating that occidiofungin is more effective in inhibiting the filamentous formation (Table 3.1
and Figure 3.3).
Table 3.1

MIC values for yeast-phase (vegetative) and morphologically switching cells
Strains
WT SC5314
WT DAY286

A.

Figure 3.3

MIC (µg/mL) (1 x 104 cells/mL)
vegetative cells
switching cells
0.5 (n=3)
0.25 (n=3)
0.5 (n=3)
0.25 (n=3)

B.

Representative MIC plate for occidiofungin sensitivity assay for yeast-phase and
switching cells

A. For yeast phase cells, an overnight culture grown at 30°C was diluted in YPD media to obtain
1 x 104 cells/mL. Occidiofungin was added to the first well to achieve a final concentration of
2µg/mL and the sample serially diluted 2-fold across the plate. Visual MIC, determined as the
first well with no growth, was recorded after 24- and 48-hours incubation at 30°C. B. For
switching cells, a 48-hour saturated culture grown at 30°C was diluted in Spider media to obtain
1 x 104 cells/mL. The indicator, resazurin, was added to 0.005% to aid in identifying wells with
viable cell growth. Visual MIC, determined as the last blue colored well, was recorded after 24and 48-hours incubation at 37°C.
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Cek1 MAPK Pathway Mutants Have Unaltered Susceptibility to Occidiofungin
In C. albicans the Cek1 MAPK signal transduction pathway is important for
morphogenic switching as mutants in this pathway are reported to have defective filament
formation and reduced virulence 98. Given that occidiofungin has been shown to negatively
impact filament formation 150, experiments were carried out to measure the impact of
occidiofungin on the Cek1 MAPK pathway. We choose to focus on three kinases upstream of
Cek1, Cst20, Ste11, and Hst7, as well as one downstream transcription factor, Cph1. Using
available homozygous deletion mutants, we monitored the differences in susceptibility to
occidiofungin exposure by determining their MIC values. Although we found that there were no
differences in susceptibility to occidiofungin among the wild type and mutant strains, we did find
that all of the tested strains were more sensitive to occidiofungin when exposed during
morphological switching than yeast grown counterparts. For all strains, the morphologically
switching cells were 2-fold more sensitive to occidiofungin than the yeast form. In both cases,
however, there was no difference between the sensitivity pattern of wild type and mutant strains
(Table 3.2).
Table 3.2

MIC values of switching and non-switching (vegetative) Cek1 MAPK pathway
mutants
Strains

MIC (µg/mL) (1 x 104 cells/mL)
vegetative cells

switching cells

WT SC5314

0.5 (n=3)

0.25 (n=3)

Δcph1 -/-

0.5 (n=3)

0.25 (n=3)

WT DAY286

0.5 (n=3)

0.25 (n=3)

Δhst7 -/-

0.5 (n=3)

0.25 (n=3)

Δste11 -/-

0.5 (n=3)

0.25 (n=3)

Δcst20 -/-

0.5 (n=3)

0.25 (n=3)
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Figure 3.4

Representative MIC plate for occidiofungin sensitivity of Cek1 MAPK pathway
mutants induced to undergo morphological switching.

Cells from saturated cultures grown at 30°C in YPD were diluted into fresh Spider media to
achieve a final concentration of 1 x 104 cells/ml. Resazurin (0.005%) was added to identify wells
with viable cells. Occidiofungin was added to first well to obtain 2 µg/ml final concentration and
samples were serially diluted 2-fold across the plate. Visual MICs were taken after 24- and 48hours of incubation.
MICs are frequently used to assay fungal susceptibility to antifungal agents. However,
these end-point assays may overlook subtle and short-lived differences in antifungal sensitivities.
Therefore, to further probe for differences in cell viability between the deletion mutants and their
corresponding wild type strains, a short-term kill kinetic assay was carried out using a 1X MIC
(1µg/mL; 1 x 104 cells/mL) dose of occidiofungin 155. In parallel, cells were spotted to a YPD
plate as a qualitative measure of antifungal activity. As seen in the spotting assay (Figure 3.5),
the fungicidal activity of occidiofungin efficiently targeted C. albicans in a time dependent
manner, however there were no significant differences apparent between the strains. Although
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the corresponding CFU data suggested subtle differences in the sensitivity of strains to
occidiofungin exposure, these differences in viable cell number were not statistically significant
(Figure 3.6 and 3.7). The homozygous mutant for two upstream kinases of the signaling
pathway, Ste11p and Hst7p, showed the greatest decline in cell viability in response to
occidiofungin exposure. The mutant for the first kinase in the pathway, Cst20p, showed some
level of resistance. It is likely that the subtle differences may be due to the different growth
pattern of the Cek1 MAPK mutants 98 and the way they respond to compensate for the cellular
stress created by occidiofungin. Additional analysis of the kill kinetic data by determining the
relative percent cell death found that the sensitivity of the mutant strains was similar to that seen
for the wild-type strain (Table 3.3).

cells/mL

Figure 3.5

106

105

104

103

102

101

106 105 104 103 102 101

Qualitative measure of susceptibility of cells to occidiofungin

Representative spotting assay depicting cell viability of treated and untreated cells for different
strains on YPD medium. The morphologically switching C. albicans were exposed to 1X MIC
(1µg/mL; 1 x 104 cells/mL) dose of occidiofungin for the time period indicated, 10-fold serially
diluted, and spotted on YPD media for growth at 30°C. Images were taken after 24- and 48-hr of
growth.
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Figure 3.6

Transcription factor mutant strain has unaltered susceptibilty to occidiofungin

Kill kinetic data for cell viability of morphologically switching cells of transcription factor
mutant strains after exposure to 1µg/mL occidiofungin (1XMIC; 1 x 104 cells/mL). The exposed
cells were spread on YPD medium following 0, 1, 2 and 4 hours of exposure. The average
CFU/mL and standard deviations are from three independent experiments.
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Figure 3.7

Kinase mutant strains have unaltered susceptibility to occidiofungin exposure

Kill kinetic data for cell viability of morphologically switching cells of kinases mutant strains
after exposure to 1µg/mL occidiofungin (1XMIC; 1 x 104 cells/mL). The exposed cells were
spread on YPD medium following 0, 1, 2 and 4 hours of exposure. The average CFU/mL and
standard deviations are from three independent experiments.
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Table 3.3

Percent cell death of wild type and mutant strains
Strains

Percent cell death
2h

4h

WT SC5314

22.8 ± 0.6

44.2 ± 4.1

cph1 -/-

26.9 ± 2.5

50.7 ± 2.2

DAY286

24.8 ± 2.2

53.4 ± 2.1

hst7 -/-

25.3 ± 3.2

51.8 ± 2.3

ste11 -/-

31.6 ± 1.3

54.7 ± 0.07

cst20 -/-

19.4 ± 2.5

50.6 ± 2.1

Percent cell death was calculated as the relative difference between the average CFU/mL for
occidiofungin-treated samples and its corresponding control 155. Values are shown as average ±
S.E. from three independent experiments. Statistical analysis of the data was performed using
Student’s t-test with a p-value <0.05 considered significant.
The Cek1 MAPK Signaling Pathway is Inhibited by Occidiofungin
Although mutants in the Cek1 MAPK pathway showed no altered susceptibility to
occidiofungin, it is still possible that occidiofungin exposure indirectly impacts components of
this filamentation pathway. To investigate this, we measured Cek1 activation post occidiofungin
treatment by immunoblot using an antibody that recognized the phosphorylated form of this
MAPK. To map the timing of Cek1p activation, wild type cells were diluted into media to induce
switching and aliquots removed at 30-minute time intervals over a 2-hour time period for
processing. Western blot data analysis found that the phosphorylated form of Cek1p was easily
detectable within 30 minutes of switching induction and exhibited 2- to 3-fold increase by 2
hours (Figure 3.8A). However, cells cultured in the presence of occidiofungin had no detectable
levels of phospho-Cek1p during the same time period.
To confirm specificity of the Cek1 phospho-antibody, samples from cst20 and cph1
deletion mutants were also analyzed under switching conditions. As shown (Figure 3.8B), a
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phosphorylated band at 49 kDa, consistent with the expected size of Cek1p, was upregulated in
the wild type strain and the cph1 mutant but not in the cst20. This is what one would expect for
proteins that work upstream (Cst20) and downstream (Cph1) of the Cek1 MAPK.

A

B

Figure 3.8

Detection of Cek1 MAPK activation by western blot.

Cells from a 48-hour saturated culture of C. albicans were diluted in Spider media to obtain an
OD600/mL of 0.05 (1.66 x 106 cells/mL) and incubated at 37°C for hyphal switching. Cells were
treated with DMSO or 1X MIC occidiofungin (1µg/mL) at the time of switching. The cells were
then collected at different time points (T= 0, 0.5, 1, 1.5 and 2h) post occidiofungin exposure by
filtration through a nitrocellulose membrane. Extracted proteins were analyzed by western blot
using antibodies against phospho-Cek1p. GAPDH was used as control to validate equal loading.
A. Representative western image for occidiofungin treated and untreated cultures. Blots were
analyzed using NIH Image J and the fold difference for phospho-Cek1p was calculated. B.
Western blots for samples from wild type, cph1 and cst20 mutant strains at T=0 to 2 hours post
switching.
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Table 3.4

Relative Cek1p phosphorylation

Time after
switching
0.5h

Mean fold
change
1

Percent
change
0

Standard
deviation
0

1h

2.27

+127%

0.97

1.5h

2.85

+185%

2.39

2h

3.60

+260%

1.82

The relative ratio of phospho-Cek1 to GAPDH was determined with T= 30 minutes normalized
to 1. The mean fold values, percent change, and standard deviation shown were calculated from
western blots assays from three independent experiments.
Occidiofungin Sensitivity Post Switching Induction
Prior work found that S. cerevisiae cells in quiescence exhibited a short-term resistance to
occidiofungin 155. The C. albicans cells used in our morphogenic switching experiments are
obtained from a saturated culture where all cells of the population exist with an unbudded G1
morphology. To determine whether the 2-fold resistance identified for occidiofungin is linked to
a property specific to saturated cells or to a particular window within the morphogenic switching
period, occidiofungin was added at different time points following switching induction and cell
sensitivity measured by MIC assays. For comparison purpose, sensitivity profiles to the
echinocandin, caspofungin, was carried out in parallel. While no difference in sensitivity was
identified based on timing of caspofungin addition post switching, occidiofungin was found to
have greater fungicidal activity on cells at later stages of switching.
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Figure 3.9

MIC assay for occidiofungin and caspofungin added at different times post
switching

Cells from a saturated culture grown at 30°C was diluted in Spider medium to obtain 0.05
OD600/mL (1.66 x 106 cells/mL) and incubated at 37°C for hyphal induction. Cells were removed
at T=0, 0.5, 1, 1.5 and 2 hours of incubation post switching for determination of occidiofungin
and caspofungin sensitivity by MIC assays. Plates were incubated at 37°C and visual MIC
recorded after 24- and 48-hours. The well with the lowest concentration of antifungal having no
visible growth (no color change of resazurin) was recorded as the MIC value. Experiments were
performed in technical duplicate for each time point for three independent experimental repeats.

Specifically, cells were most sensitive to occidiofungin 1 hour after they were induced to
undergo switching and this sensitivity profile did not change if the antifungal was added as late
as 2 hours after switching induction. The data provides additional information about the action of
occidiofungin against C. albicans as it relates to its fungicidal potential. These susceptibility
differences suggest that cells may have a higher dependence on the biological target of
occidiofungin activity during hyphal elongation than during other stages of growth.
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Occidiofungin Inhibition of Filamentation Occurs Within a Defined Time Window
Hyphal initiation is linked to the hyphal elongation phase through the establishment of a
molecular signaling pathway. Studies have reported that sustained hyphal development relies on
a transcriptional program that is established shortly after cells are inoculated into fresh media 166.
In order to investigate whether occidiofungin added within this time window had any impact on
hyphal development, cells were treated with occidiofungin (0.5µg/mL; 1.66 x 106 cells/mL) at
the time of switching, 30 minutes and 1 hour after switching induction and compared with
untreated cells (DMSO treated). The addition of occidiofungin during the hyphal initiation stage
(defined as the first 30 minutes of hyphal induction 24) was found to prevent hyphal
development. However, waiting an additional 30 minutes (i.e. 1 hour after hyphae initiation)
before the addition of occidiofungin rescued the cell’s ability to initiate hyphal development
(Figure 3.10) although it did negatively impact overall hyphal length (Figure 3.11).
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Figure 3.10

Percentage of cells in hyphae form in untreated and treated cultures

Graphical representation of the percent of hyphal cells in occidiofungin treated and untreated
cultures over a 4-hour period following induction of morphological switching. Cells from a
saturated culture were diluted into Spider media to achieve 1.66 x 106 cells/mL and placed at
37°C. Where indicated, occidiofungin (0.5µg/mL) was added at the time of switching, 30
minutes or 1 hour after switching. Samples were collected at defined time intervals thereafter and
the cells fixed in formaldehyde. Morphology was scored as yeast or hyphae by light microscopy.
A minimum of 200 cells were scored per sample. The data shows the average percentage of
hyphal cells from three independent experiments with the error bar representing standard
deviation.

Untreated (DMSO treated) cultures showed an accumulation of hyphal cells over time
reaching a maximum of ~85% of the cells in the population by 4h incubation. Although cultures
exposed to occidiofungin 1 hour after morphological induction had hyphal cells, unlike what was
seen for untreated cells, there was no significant change in the percent of the population that
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presented as hyphae over time. In addition, the percentage of hyphae at each time point was
significantly lower than for untreated cultures ranging from 55% to 60% over the following 3
hours. Therefore, to completely block hyphae formation, occidiofungin must be added within 30
minutes of switching induction.

Figure 3.11

Hyphal development and maintenance are impacted only when occidiofungin is
added within 30 minutes of switching

A montage of occidiofungin untreated and treated cells at different times following switching.
The cells were treated with 0.5µg/mL (0.5X MIC for 1.66 x 106 cells/mL) at the time of
switching (T=0), 30 minutes, or 1 hour after switching. Cells were imaged using Nikon Eclipse50 microscope at 100X magnification. Size bar = 5 µm.
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Figure 3.12

Hyphae length variations in occidiofungin treated and untreated cultures

51

C

Treated

Untreated

Figure 3.12 (continued)
Graphical representation of the distribution of hyphal lengths for cells treated and untreated with
occidiofungin. The cells were added with 0.5µg/mL of occidiofungin (0.5X MIC for 1.66 x 106
cells/mL) 1 hr following the induction of morphological switching and hyphae length determined
for cells collected at 2h and 4h post induction. Hyphae length was measured using NIH Image J
software. Representative data are shown. (A) Hyphal length variation between untreated and
occidiofungin treated cultures 2h post hyphae induction. The average and standard error are
shown. (B) Hyphal length variation between untreated and occidiofungin treated cultures 4h
following induction. (C) A violin plot depicting length measurements for hyphae formed in a set
of untreated and treated cultures over 1, 1.5, 2 and 4h post morphogenic switching. The average
is indicated with a horizontal bar.
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In addition to reducing filament length, occidiofungin addition post switching resulted in
the accumulation of a small population of cells with abnormal morphologies including multiple
branching, abnormally shaped hypha-like structures, and unusual bud-like structures (Figure
3.13). Although morphological defects were found at less than 1% percent in untreated cultures,
these morphological abnormalities increased to ~13% of the population in cultures exposed to
occidiofungin 1 hour after the induction of switching (Table 3.5).

Table 3.5

Percent cell morphology of occidiofungin untreated and treated samples at 4h
incubation (n=3)

Time of occi
treatment

Hyphae

Unbudded yeast

Budded yeast

Abnormal
morphology

1h

60.33 % ± 1.2

24.34 % ± 1.52

2.03 % ± 0.013

13.3 % ± 0.03

0.5h

8.66 % ± 0.33

82.63 % ± 0.33

6.51 % ±0.032

2.2 % ± 0.016

0h

4.33 % ± 1.45

94.95 % ± 0.88

0.54 % ± 0.002

0.18 % ± 0.0012

Control

84.33 % ±4.63

14.64 % ± 4.63

0.89 % ± 0.0001

0.14 % ± 0.0014

Cells having different morphology than that for true hyphae or yeast (budded and unbudded)
were recorded as abnormal morphology. The average percent morphology and standard errors
from three independent experiments are shown.
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Figure 3.13

Abnormal morphologies following occidiofungin addition 1h post switching
induction

A montage of representative cells from a treated culture at 4h incubation. Cells were treated with
0.5X MIC occidiofungin (0.5µg/mL; 1.66 x 106 cells/mL) 1h after switching induction and
imaged after 4h using Nikon Eclipse-50 microscope at 100X magnification. Size bar = 5µm.
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CHAPTER IV
SUMMARY
Discussion of Results
Occidiofungin has been found to be active against a wide array of clinically important
filamentous and non-filamentous fungi including species of Candida. Strains of C. albicans that
are resistant to fluconazole and echinocandin are also found to be susceptible to occidiofungin
exposure 150. Moreover, its chemical stability and minimal toxicity presents occidiofungin as a
strong candidate for clinical use. The ability of this fungus to grow as a yeast and hypha, and the
ability to switch between these two morphological forms based on changes in environmental
conditions, is an important factor of its pathogenicity 18. Therefore, effective antifungal
compounds would be ones capable of targeting both of these morphological forms. To this end,
we investigated the impact of occidiofungin on the morphogenic transformation of C. albicans.
We also investigated the impact of occidiofungin on one of the signaling cascades responsible
for hyphal formation in C. albicans, the Cek1 MAPK signaling cascade.
We demonstrated that morphologically switching cells, when exposed to a subinhibitory
dose of occidiofungin, blocked hyphal formation. These findings were consistent with the
findings of a recent study 150.
The antifungal susceptibility test for the yeast form of C. albicans against occidiofungin
has been investigated in the past 154, however this is the first report that has focused on fully
characterizing occidiofungin susceptibility for morphologically switching cells. Overall, we
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found that morphologically switching cells were 2-fold more sensitive to occidiofungin exposure
than the yeast form. This observation suggests that occidiofungin likely targets a biological
process that is important for hyphae formation. Inhibition of hyphae development is not unique
to occidiofungin as several studies have reported on the relationship between antifungal agents
and morphogenic transformation of C. albicans 164,165. For example, the fungicidal agents
amphotericin B and mulundocandin (an echinocandin family member) are reported to be
effective at blocking morphogenetic transformation, with MIC values for switching cells 2.5 to
10-fold lower than that required to inhibit the yeast form. In contrast, a higher concentration of
azoles is required for inhibition, while flucytosine, terbinafine and amorolfine appeared to have
little or no effect on morphogenic transformation 165. Our MIC assay data along with the
established link between filamentation and biofilm formation, suggests that occidiofungin may
be a useful drug to target drug resistant biofilms which contain mixed populations of yeast and
hyphae.
Studies have shown that for C. albicans cells to grow as hyphae, the hyphal transcription
program must be established long enough to accumulate the proteins required for hyphae
formation 24,166. This duration is defined as the “window of opportunity”, a period that has been
shown to be influenced by growth conditions. Knowing this, we tested the sensitivity of cells at
different stages of morphological transition to determine whether occidiofungin susceptibility
was linked to the developmental window for hyphae formation. These results were compared
with that of caspofungin, a member of the echinocandin family of antifungal agents. We
observed that the later stages of hyphal formation were more sensitive to occidiofungin than the
initial stages. Although caspofungin was more effective at killing hyphal cells, there was no
differences in sensitivity across these early stages of hyphal formation. We speculate this is
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because of the differences in targets and mechanism of action for the two antifungals. Our data
further supports that unlike caspofungin, occidiofungin targets the hyphal formation mechanism
and hence has higher inhibitory activity against filamentous form.
In C. albicans, once hyphal development is initiated, maintenance of hypha growth
requires sensing of the growth conditions 24. The hyphal cells continue to grow under nutrient
starvation, high CO2 level or hypoxia and can convert into yeast form when nutrients are replete.
The strength and duration of the hyphal initiation program in each cell requires the cAMP-PKA
pathway and the hyphal development program is maintained through the TOR pathway. The
hyphal transcriptional program is initiated with the removal of transcriptional repressors. In a
laboratory setting, the timing and efficiency of hyphal initiation depends on multiple factors
including the growth status of the inoculum, the fold culture dilution, the media and temperature
used for switching induction. Our data indicates that the window of susceptibility to
occidiofungin during hyphal initiation is between 30 minutes and 1 hour of hyphal induction as
the addition of occidiofungin within this window inhibited hyphal formation. This timing is
consistent with a report by Lu et al., 2011 showing that the addition of rapamycin and serum
after 2h of hyphal induction had no effect on hyphal maintenance 24. One possible explanation
may be linked to the differences in metabolic status of the cells at these two stages of
susceptibility testing, with actively growing cells more susceptible to occidiofungin bioactivity.
Prior work carried out in S. cerevisiae has shown that resistance to occidiofungin occurs for
quiescent cells, for the first hour after quiescent cells are diluted into fresh media, and for cells
that are blocked for growth due to the absence of glucose in the media or the presence of a
cytosolic protein synthesis inhibitor 155. After 48 hours of growth, C. albicans will have switched
from fermentative growth into respiratory growth with the complete metabolism of glucose, and
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may have even depleted available ethanol resources 167. This change in metabolism will be
accompanied by altered transcriptional profiles which may impact cell sensitivity to antifungal
compounds possibly through the alteration of processes involved in endocytosis, cell wall
production, and/or stress resistance mechanisms.
Next, we examined the impact of occidiofungin on Cek1 MAPK activation using western
blot analysis. Cek1 activation is impacted by different environmental signals. When a
synchronized culture of cells are diluted in fresh media with nitrogen limitation, the level of
Cek1 peaks in 1-2 hours and decrease as the cells re-enter stationary phase 97. Similarly, we
found that the level of activated Cek1, as determined by Cek1 phosphorylation, was highest in
untreated cells 2 hours after the induction of switching. However, phospho-Cek1 was
undetectable in occidiofungin treated cells. This indicates that the Cek1 MAPK pathway was not
activated in occidiofungin treated cells during this same time period. We speculate that
occidiofungin may be playing a repressive role in Cek1 activation/phosphorylation and inhibits
filamentation in similar manner as farnesol-mediated repression of dimorphic transition.
However, the data from hyphal length determination for cells where occidiofungin was added
post-switching indicate that unlike farnesol, occidiofungin not only inhibits hyphae formation but
also negatively impacts the hyphal elongation process 94. Our MIC and CFU data for the Cek1
MAPK mutants suggest that a functional Cek1 MAPK signaling pathway is not required for
occidiofungin activity, which supports the finding that Cek1 MAPK pathway is required but not
essential for filamentation in C. albicans 98. The data further indicate that occidiofungin may be
acting upstream of Cst20, possibly through the Ras protein which supports studies that have
reported that the MAP kinase pathway does not function as the central controller of hyphal
development 92.
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The most recent study has identified actin as the biological target of occidiofungin 150.
Previous studies have shown that actin dynamics are necessary for the maintenance of many
different cellular functions, including being linked to the Ras-cAMP-protein kinase pathway
168,169

. Of most relevance is the observation that polarization of the actin cytoskeleton is required

for hyphae formation 170. Data from our study indicates that the target of occidiofungin is likely
functioning upstream of Cst20p, which correlates with the relationship between actin dynamics
and activation of Ras-cAMP-protein kinase pathway. This suggests that occidiofungin’s impact
on the actin cytoskeleton may negatively regulate cellular pathways required for the initiation or
maintenance of filamentation 171.
Actin dynamics has been found to influence the expression of the hyphae associated
gene, HWP1. For example, HWP1 gene expression is upregulated in cells treated with the actin
filament stabilizer, jasplakinolide, and downregulated in cells treated with actin destabilizers like
lantranculin A and cytochalasin A 169. Additional evidence linking actin dynamics with Ras1p
activity are the findings that stabilization of actin triggers hyperactivation of the Ras mediated
cAMP/PKA signaling cascade 172. Ras signaling through Cyr1(adenylyl cyclase) requires
Srv2/CAP, a protein that has a dual role in activating Cyr1 and in actin binding and regulation. In
actin stabilized cells, Cyr1 and Srv2 colocalize with F-actin aggregates, Ras1 is constitutively
active, and signaling through the cAMP/PKA pathway occurs leading to hyphal development.
Occidiofungin has been reported to interact with actin directly 150 and it is possible that binding
of occidiofungin to actin prevents the association of Ras and Srv2/CAP thereby resulting in
downregulation of the pathway. More likely is the possibility that occidiofungin exposure
destabilizes F-actin filaments, which leads to loss of Ras1 activity and inhibition of the
downstream signaling required for hyphal formation.
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Conclusions and Future Directions
The overall aim of this research was to address how occidiofungin inhibits filamentation
in C. albicans. In the case of C. albicans, inhibition of morphogenesis is an excellent target for
antifungal compounds. Such antifungal agents may create less selective pressure by still allowing
the cells to grow, slowing down the acquisition of drug resistance. It is evident from our study
that occidiofungin is more effective in inhibiting the hyphal form of C. albicans than the yeast
form. However, the results of our study are all based on filamentation in liquid media which only
mimics the filamentation process that occurs in the bodily fluids or within the phagocytic cells of
the infected host. Future studies on occidiofungin bioactivity against morphogenic switching
needs to be carried out on solid surfaces as a model for filamentation on endothelial or epithelial
surfaces within the host body.
Significant work has been done to understand the polymorphism of C. albicans including
the ability of these fungi to form biofilms. Given that biofilm formation has been linked to
antifungal resistance, future studies addressing the efficacy of occidiofungin against biofilm
requires further testing. As a mixed cell population of yeast and hyphae, occidiofungin would be
effective at targeting all cells for elimination. Further studies on these aspects could potentially
help establish occidiofungn as an effective alternative antifungal treatment. Given the role of
filamentation in invasive C. albicans infections, antifungals that specifically target inhibition of
the yeast-to-hyphae switch could be a promising option for controlling life-threatening
infections.
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Genes involved in hyphae formation and regulation in C. albicans
Table A.1

Genes involved in cAMP signaling pathway

Gene (product)
BCY1
(Bypass of CyclicAMP requirement)
CDC24
(Cell Division Cycle)
CDC42
(Cell Division Cycle)
CSC25
(C. albicans
Suppressor of Cdc25)
CYR1
(Cyclic AMP
Requirement)
EFG1
(Enhanced
Filamentous Growth)
IRA2
(Inhibitory Regulator
of the RAS-cAMP
pathway)
PDE1/PDE2
(PhosphoDiEsterase)
RAS1
(homologous to RAS
proto-oncogene)
SRV2
(Supressor of
RasVal19)
TPK1/TPK2
(Takashi’s Protein
Kinase)

Description
Role
Protein kinase A
Regulation of filamentation,
regulatory subunit phenotypic switching and mating;
required for nuclear localization of
Tpk1
GDP-GTP
Required for maintenance of hyphal
exchange factor
growth; involved in bud site
(GEF) for Cdc42p selection, septin ring organization
Rho-type GTPase Required for budding and
maintenance of hyphal growth;
hyphal tip localization is actindependent
GDP-GTP
Activator of Ras/adenylyl cyclase
exchange factor
pathway
(GEF) for Ras1p
Adenylyl cyclase Required for conversion of ATP to
cAMP; regulates filamentation and
phenotypic switching
Transcription
Controls genes required for cell wall
factor
production, hyphal growth, and
biofilm formation
GTPaseNegatively regulates RAS by
activating protein stimulating GTP to GDP conversion
(GAP) for Ras1p

Source
1, 2

Cyclic nucleotide Mediates cAMP signaling in
phosphodiesterase response to glucose; required for
; cleaves cAMP
virulence, switching, cell wall and
hyphal growth
GTPase
Regulates cAMP and MAP kinase
pathways; role in hyphal induction

1

Adenylate
cyclaseassociated protein
(CAP)
cAMP-dependent
protein kinase
catalytic subunit

1

Regulates adenylate cyclase activity,
required for germ tube formation
Phosphorylates Efg1; regulates
filamentation, phenotypic switching
and mating
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1
1

1
1, 2
1
1

1

Table A.2

Genes involved in MAPK signaling pathway

Gene (product)
CEK1
(C. albicans ERK-like
Kinase)
CEK2
(C. albicans ERK-like
kinase)
CHK1
(C. albicans Histidine
Kinase)
CPH1
(Candida
PseudoHyphal
regulator)
CST20
(C. albicans STe20)

Description
MAP kinase

Role
Required for wild-type yeast-hypha
switch, mating, virulence and invasive
growth
Required for wild-type efficiency of
mating

Source
1

Phosphorelay sensor kinase activity;
role in cell wall synthesis, positive
regulation of filamentous growth
Positive regulator of filamentous
growth in response to stimulus

1

Required for wild-type mating
efficiency and hyphal growth
regulation
Regulates filamentous growth;
involved in cAMP-mediated glucose
signaling; regulates HWP1 and ECE1
cAMP-PKA pathway receptor;
required for hyphal growth

1

GPA2
(G-Protein Alpha
subunit)
GPR1
(G-protein coupled
receptor)
HOG1
(High Osmolarity
Glycerol response)
HST7
(Homolog of S.
cerevisiae STe7)
MEP2
(Ammonium
Permease)

Alpha subunit of
a heterotrimeric
G protein
G-protein
coupled receptor
MAP kinase

Role in regulation in response to stress
and filamentous growth

1

MAP kinase
kinase

Involved in mating and hyphal
growth; phosphorylates Cek1p

1

Ammonium
transmembrane
transporter

Regulator of nitrogen starvationinduced filamentation; activates
Ras/cAMP and MAPK signaling
pathways to induce filamentation
Role in biofilm formation and contactinduced invasive filamentation

1

MKC1
(MAP Kinase from C.
albicans)
MKK1/MKK2
(MAP Kinase Kinase)
MSB2
(Multicopy
Suppression of a
Budding defect)

MAP kinase
Protein kinase

Protein kinase of Mkc1 pathway

1

Cell wall
damage sensor

Required for Cek1 phosphorylation by
cell wall stress

1, 2

MAP kinase
Histidine kinase
Transcription
factor
Protein kinase
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1

1

1
1

1

Table A.2 (continued)
NIK1
(NIm1 related protein
Kinase)
PBS2
(Polymixin B
Sensitivity)

Histidine kinase

PKC1
(Protein Kinase C)
SHO1
(Synthetic High
Osmolarity Sensitive)

Protein kinase C

Role for normal cell morphology

Predicted adaptor
protein involved
in activation of
MAPK pathway
Histidine kinase

Links response to oxidative stress to
morphogenesis and cell wall biogenesis

1, 2

Phosphorelay sensor kinase activity,
regulates cell wall biosynthesis

1, 2

Response
regulator of two
component system
MAP kinase
kinase kinase

Role in oxidative stress, cell wall
biosynthesis, hyphal growth on solid
media
Regulates Hog1 activation

1, 2

MAP kinase
kinase kinase
Phosphotransferas
e

Regulates Cek1 activation, hyphal growth

1, 2

Phosphorelay intermediate sensor protein
of the Hog1 pathway

1, 2

SLN1
(Synthetic Lethal of Nend rule)
SSK1
(Supressor of Sensor
Kinase)
SSK2
(Supressor of Sensor
Kinase)
STE11
(STErile 11)
YPD1
(tYrosine Phosphatase
Dependent)

Table A.3

MAP kinase
kinase

Phosphorelay sensor kinase activity,
regulates cell wall biosynthesis,
required for wild-type virulence
Role in osmotic and oxidative stress
response, required for regulation of
Hog1p localization

1, 2
1, 2

1, 2

Genes required for hyphal repression

Gene (product)
NRG1
(Negative Regulator of
Glucose-repressed
genes)
RFG1
(Repressor of
Filamentous Growth)
TUP1
(dTMP-Uptake)

Description
Transcriptional
repressor

Role
Regulates hyphal gene induction in a
Tup1-dependent and independent
manner

Source
1, 2

HMG domain
transcriptional
repressor
Transcriptional
co-repressor

Represses filamentous growth and
hyphal genes in a Tup1-dependent and
independent manner
Represses filamentous growth along
with Nrg1 and Rfg1, regulates
switching, role in germ tube induction

1
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1, 2

Table A.4

Actin-associated genes

Gene (product)
ARP2/3
(Actin-Related Protein)
PAN1
(Poly(A)-binding protein
dependent poly(A)
riboNuclease)
SLA1
(Synthetic Lethal with
ABP1)
SLA2
(Synthetic Lethal with
ABP1)

Table A.5

Description
Actin nucleator
Part of actin
cytoskeletonregulatory
complex
SH3 containing
protein
Actin binding
protein

Role
Required for motility and
integrity of actin patches
Involved in endocytosis and
polarized growth; regulates actin
cytoskeleton

Source
2

Required for assembly of the
cortical actin cytoskeleton

1, 2

Growth control and
morphogenesis; required for
alkaline pH-induced hyphal
formation

1, 2

1, 2

Hyphae-associated genes

Gene (product)
ECE1
(Extent of Cell
Elongation)
HWP1
(Hyphal Wall Protein)
HYR1
(HYdroperoxide
Resistance)
RBT1
(Repressed by TUP1)
RBT4
(Repressed by TUP1)
RBT5
(Repressed by TUP1)
RBT7
(Repressed by TUP1)

Description
Cytolytic peptide

Role
Hypha specific protein,
essential for mucosal infection

Source
1

Hyphal cell wall protein

Promotes host cell adhesion

1

GPI-anchored protein

Hyphal cell wall protein

1

Cell wall protein similar
to HWP1
Pry family protein

Required for virulence, hyphal
growth
Required for virulence,
filamentation
Required for virulence, biofilm
formation; role in iron uptake
Function unknown

1, 2

GPI-linked cell wall
protein
Putative RNase activity
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1, 2
1, 2
1, 2

Table A.6

Other related genes

Gene (product)
AGP2
(high Affinity
Glutamine Permease)
DFG16
(Defective for
Filamentous Growth)
CDR1
(Candida Drug
Resistance)
ERG1
(ERGosterol
biosynthesis)
FKS1
(FK506 Sensitivity)
RIM101
(Regulator of IME2)

Description
Amino acid permease

Role
Transmembrane transport;
hyphal repressed; induced in
core caspofungin response
Regulates filamentation in
response to alkaline pH by
acting in Rim101 processing
Multi drug transporter;
phospholipid exporter

Source
1, 2

Squalene epoxidase

Catalyzes the epoxidation of
squalene to 2,3-oxisqualene

1

Catalytic subunit of 1,3beta-D-glucan synthase
Cys2-His2 zinc-finger
transcription factor

Involved in cell wall synthesis 1, 2
and maintenance
Required for alkaline induced 1, 2
hyphal growth; activated by Cterminal proteolytic cleavage
Rim101 cleavage
1, 2

Putative G-protein
coupled receptor
ABC superfamily
member

RIM13
Endopeptidase activity
(Regulator of IME2)
RIM21
Plasma membrane pH
Required alkaline pH induced
(Regulator of IME2)
sensor
hyphal growth
Source: 1- Candida Genome Database, http://www.candidagenome.org/
2- Saccharomyces Genome Database, https://www.yeastgenome.org/

Cell number and MIC values
Table A.7

MIC values for corresponding cell numbers
1X MIC for C. albicans

Vegetative
Cell number
(cells/mL)
1 x 104
0.5µg/mL
6

1.66 x 10

2µg/mL

At time of
switching

30 minutes post
switching

1-2 hrs post
switching

0.25µg/mL

Not Determined

Not Determined

1µg/mL

1µg/mL

0.5µg/mL

82

1, 2
1

1, 2

